Mon, 18th Nov 2013 09:27
LONDON (Alliance News) - Imperial Innovations Group PLC Monday said it had committed GBP4.5 million to a GBP20 million funding round launched by MISSION Therapeutics, one of its portfolio companies.
It said the new financing will allow Mission to advance its cancer treatment programmes.
Imperial Innovations last traded at 412.5 pence.
By Steve McGrath; stevemcgrath@alliancenews.com; @SteveMcGrath1
Copyright © 2013 Alliance News Limited. All Rights Reserved.
AIM WINNERS & LOSERS: In The Style shares shredded by profit warning
(ShareCast News) - Imperial Innovations Group announced on Thursday that, further to the shareholder approval received at its AGM on 21 November 2016,...
(ShareCast News) - Imperial Innovations Group announced on Friday that at its annual general meeting on 21 November, it will be seeking shareholder ap...
(ShareCast News) - Imperial Innovations Group noted on Monday that its portfolio company, Veryan Medical, has completed enrolment into the MIMICS-2 cl...